Antigen receptors are proteins on the surface of immune cells that detect and bind to foreign substances like bacteria, viruses, and toxins. They are the molecular sensors that allow your immune system to distinguish threats from your own healthy tissue. The two main types sit on B cells and T cells, the white blood cells responsible for most of your body’s targeted immune defenses.
The Two Main Types
Your immune system relies on two kinds of antigen receptors, each built from a different set of proteins but following a similar architectural blueprint. B cell receptors (BCRs) sit on the surface of B cells, while T cell receptors (TCRs) sit on T cells. Both are multi-chain protein complexes with two core jobs: grabbing onto a specific piece of a pathogen and then relaying a signal inside the cell that triggers an immune response.
B cell receptors are essentially antibodies anchored to the cell membrane. Each one is a complex of six protein chains: two identical heavy chains and two identical light chains that form the Y-shaped structure you may have seen in textbook illustrations, plus two smaller signaling chains. The tips of the Y contain the antigen-binding sites, and each BCR can latch directly onto a pathogen’s surface proteins, sugars, or fats without any intermediary. When a B cell is activated, it can release its receptors as free-floating antibodies into the bloodstream.
T cell receptors work differently. Each TCR is built from two variable chains that form a single binding site, paired with a cluster of signaling chains. The critical distinction is that TCRs cannot recognize a pathogen on their own. Instead, they only respond to small protein fragments (peptides) that have been chopped up and displayed on the surface of other cells by specialized presenter molecules called MHC. This means T cells are scanning your own cells for signs of infection or abnormality rather than directly engaging whole pathogens the way B cells do. Every TCR structure studied to date confirms this rule: the receptor always contacts both the peptide fragment and the MHC molecule presenting it.
How Your Body Creates Millions of Unique Receptors
One of the most remarkable features of antigen receptors is their diversity. Your body needs to be prepared for pathogens it has never encountered, so it generates an enormous variety of receptors, each shaped to bind a slightly different target. It does this through a genetic cut-and-paste process called V(D)J recombination that happens as immune cells develop.
The genes encoding the business end of each receptor aren’t stored as a single continuous sequence. Instead, they exist as collections of smaller gene segments labeled V (variable), D (diversity), and J (joining). During development, each immature immune cell randomly selects one segment from each group and physically stitches them together by cutting and rejoining its own DNA. Two specialized enzymes, RAG1 and RAG2, carry out these cuts. The process is orderly: D segments join to J segments first, and then a V segment is attached to the DJ combination.
This combinatorial assembly alone produces substantial variety, since there are dozens of possible segments in each category. But the real explosion of diversity comes from imprecision at the joints. When the DNA segments are cut and reconnected, small numbers of nucleotides (the individual “letters” of DNA) are randomly added or deleted at the junction points. This junctional variability means that even two cells choosing the same V, D, and J segments will almost certainly end up with slightly different receptors. The result is a repertoire of billions of unique receptor shapes generated from a surprisingly compact stretch of genetic code.
How Receptors Trigger an Immune Response
Recognizing an antigen is only half the job. The receptor also has to send a signal inside the cell to kick off an immune response. Both BCRs and TCRs accomplish this through short signaling sequences on their interior tails called ITAMs (immune-receptor tyrosine-based activation motifs). When an antigen binds the receptor’s outer surface, enzymes inside the cell add phosphate groups to these ITAMs, creating docking sites for downstream signaling molecules. This sets off a cascade of chemical events that ultimately tells the cell to activate, multiply, and fight.
The two receptor types differ in their signaling capacity. A B cell receptor carries 2 ITAMs total. A T cell receptor complex is far more heavily equipped, with 10 ITAMs spread across its various signaling chains. This larger number may give T cells greater flexibility in how they respond to different signals, allowing for more nuanced control over activation.
Quality Control: Eliminating Dangerous Receptors
Because receptor assembly is random, some newly made receptors will inevitably bind to your own tissues rather than foreign invaders. Left unchecked, these self-reactive receptors would cause autoimmune disease. Your body prevents this through a screening process during immune cell development.
For T cells, this quality check happens in the thymus. Developing T cells are tested against samples of the body’s own proteins displayed on MHC molecules. The outcome depends entirely on how strongly the receptor binds. A weak interaction signals that the receptor is functional but not dangerously self-reactive, and the cell survives (positive selection). A strong interaction with self proteins marks the cell as a threat, and it is killed off through programmed cell death (negative selection). Cells whose receptors fail to bind anything at all also die, since a nonfunctional receptor is useless. Only T cells that pass both tests, binding self-MHC weakly but not strongly, graduate into the circulating immune system.
Some T cells that bind self-proteins moderately are redirected into becoming regulatory T cells, a specialized population that actively suppresses immune attacks against the body’s own tissues. This adds another layer of protection against autoimmunity.
B Cell Receptors Improve Over Time
B cell receptors have a capability that T cell receptors lack: they can refine their binding strength during an active infection. This process, called affinity maturation, takes place in specialized structures within lymph nodes called germinal centers.
When B cells are activated by a pathogen, they enter germinal centers and begin dividing rapidly. With each division, their receptor genes accumulate random mutations at a rate of roughly 1 in 1,000 per DNA base pair per division. Most of these mutations are harmful or neutral, making the receptor worse or having no effect. But occasionally, a mutation improves the fit between the receptor and its target. B cells carrying improved receptors compete more successfully for limited help from nearby T cells. Those that win this competition are selected to keep dividing, while those with weaker receptors die off.
This cycle of mutation, competition, and selection repeats over days to weeks, progressively sharpening the immune response. The result can be dramatic: serum antibody binding strength can increase 100-fold over the course of an infection. Recent research in mice has revealed that the highest-performing B cells may actually reduce their mutation rate during rapid division, protecting their improved receptors from being degraded by further random changes. B cells also undergo a separate process called class-switch recombination, which changes the type of antibody they produce (for instance, from IgM to IgG) to better suit the kind of immune response needed.
Gamma-Delta T Cell Receptors
Most T cells carry receptors built from alpha and beta chains, but a smaller population uses a different pair: gamma and delta chains. These gamma-delta T cells make up just 0.5 to 10 percent of T cells in the blood but are heavily concentrated in barrier tissues like the skin, lungs, and intestinal lining.
Gamma-delta receptors break several of the rules that govern conventional T cell receptors. They can recognize targets without needing MHC presentation, which means they respond to threats regardless of a person’s specific genetic makeup. Their targets include stress molecules that flag DNA damage, viral infection, or cancerous transformation, as well as certain fats and small metabolic byproducts. The binding region of the delta chain tends to be longer and more variable than that of conventional TCRs, resembling B cell receptors in this respect. This structural flexibility may explain why gamma-delta receptors can detect such a wide range of molecules.
Unlike conventional T cells, which develop their functional identity after encountering a pathogen, gamma-delta T cells appear to have their roles pre-programmed during development in the thymus. Their ability to recognize stressed or abnormal cells without MHC restriction has made them an active area of interest for cancer immunotherapy, since treatments based on these cells could potentially work across all patients without needing to be matched to individual genetics.
Engineered Antigen Receptors in Medicine
The principles behind natural antigen receptors have inspired one of the most significant advances in cancer treatment: chimeric antigen receptors, or CARs. These are synthetic receptors designed in a lab and inserted into a patient’s own T cells to redirect them against tumor cells.
A CAR typically combines an antibody fragment on the outside (to recognize a specific protein on cancer cells) with signaling components on the inside (to activate the T cell). The earliest designs, called first-generation CARs, contained only a basic activation signal. Second-generation CARs added a costimulatory domain that helps the T cell survive longer and mount a stronger response. Third-generation CARs include two costimulatory domains for even greater potency. The choice of spacer region connecting the outer binding domain to the cell membrane also affects how well the receptor works, since it influences the receptor’s ability to reach its target on the tumor cell surface.
CAR-T cell therapy has proven especially effective against certain blood cancers. It represents a practical application of decades of basic research into how antigen receptors are built, how they signal, and how they can be repurposed to fight disease.